|Bid||85.39 x 1400|
|Ask||85.55 x 900|
|Day's Range||84.92 - 88.08|
|52 Week Range||32.96 - 195.99|
|Beta (5Y Monthly)||0.99|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 07, 2022 - Nov 11, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||118.46|
Subscribe to Yahoo Finance Plus to view Fair Value for MRTX
Mirati Therapeutics, Inc. ( NASDAQ:MRTX ) shareholders will have a reason to smile today, with the analysts making...
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced that the company granted equity awards to 56 new employees with a grant date of August 1, 2022, as equity inducement awards outside of the company's 2022 Equity Incentive Plan (but under the terms of the company's Inducement Plan) and material to the employees' acceptance of employment with the company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).